March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
A Randomized, Double-Masked Trial of Topical Dexamethasone 0.1%/Povidone-iodine 0.4% versus Artificial Tears for Treatment of Viral Conjunctivitis
Author Affiliations & Notes
  • Roberto D. Pinto, Sr.
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Joao Paulo F. Felix
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Rafael S. Zacchia
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Ricardo Y. Abe
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Andre V. Pereira
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Rodrigo P. Lira
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Carlos Eduardo L. Arieta
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Rosane S. Castro
    Ophthalmology, UNICAMP, Campinas, Brazil
  • Footnotes
    Commercial Relationships  Roberto D. Pinto, Sr., None; Joao Paulo F. Felix, None; Rafael S. Zacchia, None; Ricardo Y. Abe, None; Andre V. Pereira, None; Rodrigo P. Lira, None; Carlos Eduardo L. Arieta, None; Rosane S. Castro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3987. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roberto D. Pinto, Sr., Joao Paulo F. Felix, Rafael S. Zacchia, Ricardo Y. Abe, Andre V. Pereira, Rodrigo P. Lira, Carlos Eduardo L. Arieta, Rosane S. Castro; A Randomized, Double-Masked Trial of Topical Dexamethasone 0.1%/Povidone-iodine 0.4% versus Artificial Tears for Treatment of Viral Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3987.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if topical dexamethasone 0.1%/povidone-iodine 0.4% relieves the symptoms and signs of viral conjunctivitis better than artificial tears.

Methods: : Eighty-two patients with a clinical diagnosis of viral conjunctivitis were randomized to treatment group or control group. Physicians and patients were masked to treatment. Patients in the treatment group received topical dexamethasone 0.1%/povidone-iodine 0.4% four times daily, and patients in the control group received artificial tears four times daily, both during seven days. Symptom and sign scores were recorded on the day of recruitment and at the time of a follow-up examination 5, 10 and 30 days later. TheOutcome Measures werechange in six symptoms of conjunctivitis (overall discomfort, itching, foreign body sensation, tearing, redness, and lid swelling) and four signs of conjunctivitis (conjunctival injection, conjunctival chemosis, conjunctival mucus, and lid edema). Adverse effects, intra ocular pressure and subephitelial corneal infiltrates incidence were also studied.

Results: : There was no statistically significant difference between the change in symptom and signs scores between the treatment group and control group in any follow-up days, except itching and conjunctival mucus in day 10. Patients in the control group, in assessing the tenth day, were more likely to report improvement in itching than those in the treatment group, P = 0.037, and presented better evolution in conjuctival mucus, P = 0.006. There is no statistically significant difference in adverse effects, intra ocular pressure and subephitelial corneal infiltrates incidence between two groups.

Conclusions: : Topical dexamethasone 0.1%/povidone-iodine 0.4% used four times daily is no better than artificial tears at relieving the symptoms or signs of viral conjunctivitis.

Clinical Trial: : http://www.clinicaltrials.gov NCT01481519

Keywords: conjunctivitis • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • antiviral drugs 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×